Clopidogrel

Generic Name
Clopidogrel
Brand Names
Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Drug Type
Small Molecule
Chemical Formula
C16H16ClNO2S
CAS Number
113665-84-2
Unique Ingredient Identifier
A74586SNO7
Background

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication

1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者,可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点;

2.用于急性冠状动脉综合征(不稳定心绞痛和非ST段抬高心肌梗死)患者;

3.用于冠状动脉支架置入术后预防支架内血栓形成(与阿司匹林联用)。

Associated Conditions
Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
Associated Therapies
-

Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation

First Posted Date
2010-11-03
Last Posted Date
2011-07-20
Lead Sponsor
Sir Run Run Shaw Hospital
Target Recruit Count
5232
Registration Number
NCT01233167

An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of Clopidogrel

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-09-28
Last Posted Date
2011-10-07
Lead Sponsor
AstraZeneca
Target Recruit Count
58
Registration Number
NCT01210339
Locations
🇸🇪

Research Site, Uppsala, Sweden

Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation

First Posted Date
2010-09-01
Last Posted Date
2016-11-15
Lead Sponsor
Yonsei University
Target Recruit Count
630
Registration Number
NCT01192724
Locations
🇰🇷

Wonju Christian Hospital, Wonju, Gangwon, Korea, Republic of

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.

First Posted Date
2010-08-04
Last Posted Date
2012-07-04
Lead Sponsor
Ascopharm Groupe Novasco
Target Recruit Count
82
Registration Number
NCT01175200
Locations
🇫🇷

Pitié Salpétrière Hospital, Paris, France

Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-08-04
Last Posted Date
2015-03-17
Lead Sponsor
Gangnam Severance Hospital
Target Recruit Count
795
Registration Number
NCT01174693
Locations
🇰🇷

Department of Neurology, Wonju Christian Hospital, Yonei University Wonju College of Medicine, Wonju-si, Gangwon-do, Korea, Republic of

🇰🇷

Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of

🇰🇷

Department of Neurology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam-si, Gyeonggi-do, Korea, Republic of

and more 15 locations

Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-07-09
Last Posted Date
2013-08-28
Lead Sponsor
University of Zagreb
Target Recruit Count
200
Registration Number
NCT01159639
Locations
🇭🇷

Medical school Zagreb, University hospital center Zagreb, Zagreb, Croatia

Aspirin and Plavix Following Coronary Artery Bypass Grafting

First Posted Date
2010-07-08
Last Posted Date
2015-05-19
Lead Sponsor
Ahmad Slim
Target Recruit Count
20
Registration Number
NCT01158703
Locations
🇺🇸

Brooke Army Medical Center, San Antonio, Texas, United States

A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization

Phase 4
Conditions
First Posted Date
2010-07-07
Last Posted Date
2010-07-12
Lead Sponsor
CCRF Consulting Co., Ltd.
Target Recruit Count
1900
Registration Number
NCT01157455
Locations
🇨🇳

Fuwai Hospital, Beijing, China

Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis

First Posted Date
2010-07-02
Last Posted Date
2010-11-16
Lead Sponsor
University of Patras
Target Recruit Count
70
Registration Number
NCT01155765
Locations
🇬🇷

Patras University Hospital, Patras, Achaia, Greece

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

First Posted Date
2010-06-22
Last Posted Date
2011-06-28
Lead Sponsor
AstraZeneca
Target Recruit Count
149
Registration Number
NCT01147588
Locations
🇺🇸

Research Site, Overland Park, Kansas, United States

© Copyright 2024. All Rights Reserved by MedPath